Dose Prediction for Repurposing Nitazoxanide in SARS‐CoV‐2 Treatment or Chemoprophylaxis by Rajoli, Rajith K.R. et al.
 
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/bcp.14619 
 
This article is protected by copyright. All rights reserved. 
David Christopher (Orcid ID: 0000-0001-8504-2354) 
Owen Andrew (Orcid ID: 0000-0002-9819-7651) 
 
Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or 
Chemoprophylaxis 
Rajith K.R. Rajoli1, Henry Pertinez1, Usman Arshad1, Helen Box1, Lee Tatham1, Paul Curley1, 
Megan Neary1, Joanne Sharp1, Neill J. Liptrott1, Anthony Valentijn1, Christopher David1, 
Steven P. Rannard2, Ghaith Aljayyoussi3, Shaun H. Pennington3, Andrew Hill1, Marta Boffito4,5, 
Steve A. Ward3, Saye H. Khoo1, Patrick G. Bray6, Paul M. O’Neill2, W. David Hong2, Giancarlo 
Biagini3, Andrew Owen1. 
 
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, 
University of Liverpool, Liverpool, L7 3NY, UK 
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK 
3Centre for Drugs and Diagnostics, and Department of Tropical Disease Biology, Liverpool 
School of Tropical Medicine, Liverpool L3 5QA, UK 
4Chelsea and Westminster NHS Foundation Trust and St Stephen’s AIDS Trust 4th Floor, 
Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK 
5Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College, London, 
W2 1PG, UK 
6Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK 
 
Author for correspondence: 
Professor Andrew Owen 
Department of Molecular and Clinical Pharmacology 
Materials Innovation Factory 
University of Liverpool 
51 Oxford Street,  
Liverpool L7 3NY 
United Kingdom 
Email - aowen@liverpool.ac.uk 
Phone - +44 (0)151 795 7129 
Key words: COVID-19, SARS-CoV-2, Coronavirus, Pharmacokinetics, Lung 
Figure count - 3 
Table count – 3 
 
Conflicts of interest statement 
AO and SPR are Directors of Tandem Nano Ltd. AO has received research funding from ViiV, 
Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. 
PON is currently engaged in a collaboration with Romark LLC but this interaction did not 
 
 
This article is protected by copyright. All rights reserved. 
influence the prioritisation or conclusions in the current manuscript. No other conflicts are 
declared by the authors. 
 
Funding 
The authors received no funding for the current work. AO acknowledges research funding 
from EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European 
Commission (761104) and Unitaid (project LONGEVITY). GAB acknowledges support from 
the Medical Research Council (MR/S00467X/1). GA acknowledges funding from the MRC 
Skills Development Fellowship. 
 
Principal investigator statement 
The authors confirm that the PI for this paper is Andrew Owen and the study informs dosing 
optimisation using a mathematical model without any involvement of actual patients. 
 
Running head – Nitazoxanide for SARS-CoV-2 therapy  
 
 
This article is protected by copyright. All rights reserved. 
Abstract 
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been 
declared a global pandemic and urgent treatment and prevention strategies are needed.  
Nitazoxanide, an anthelmintic drug has been shown to exhibit in vitro activity against SARS-
CoV-2. The present study used physiologically-based pharmacokinetic (PBPK) modelling to 
inform optimal doses of nitazoxanide capable of maintaining plasma and lung tizoxanide 
exposures above the reported SARS-CoV-2 EC90. 
Methods: A whole-body PBPK model was validated against available pharmacokinetic data 
for healthy individuals receiving single and multiple doses between 500–4000 mg with and 
without food. The validated model was used to predict doses expected to maintain 
tizoxanide plasma and lung concentrations above the EC90 in >90% of the simulated 
population. PopDes was used to estimate an optimal sparse sampling strategy for future 
clinical trials. 
Results: The PBPK model was successfully validated against the reported human 
pharmacokinetics. The model predicted optimal doses of 1200 mg QID, 1600 mg TID, 2900 
mg BID in the fasted state and 700 mg QID, 900 mg TID and 1400 mg BID when given with 
food. For BID regimens an optimal sparse sampling strategy of 0.25, 1, 3 and 12h post dose 
was estimated. 
Conclusion: The PBPK model predicted tizoxanide concentrations within doses of 
nitazoxanide already given to humans previously. The reported dosing strategies provide a 
rational basis for design of clinical trials with nitazoxanide for the treatment or prevention 
of SARS-CoV-2 infection. A concordant higher dose of nitazoxanide is now planned for 
investigation in the seamless phase I/IIa AGILE trial (www.agiletrial.net).   
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Introduction 
 
COVID-19 is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) with noticeable symptoms such as fever, dry cough, and difficulty in breathing 
[1]. There are currently no effective treatment or prevention options and it has become a 
global health problem with more than 3.1 million cases and over 217,000 deaths as of 29th 
April 2020 [2]. Urgent strategies are required to manage the pandemic and the repurposing 
of already approved medicines is likely to bring options forward more quickly than full 
development of potent and specific antivirals. Antiviral drugs may have application prior to 
or during early infection, but may be secondary to immunological interventions in later 
stages of severe disease [3]. 
 
Although new chemical entities are likely to have high potency and specificity for SARS-CoV-
2, full development is time consuming, costly and attrition in drug development is high [4, 
5]. Drug repurposing, where existing or investigational drugs could be used outside the 
scope of their original indication may present a rapid alternative to new drug development. 
Several examples of successful repurposing exist, including the use of the anti-angiogenic 
drug thalidomide for cancer, the use of mifepristone for Cushing’s disease after initially 
being approved for termination of early pregnancy, and the repurposing of sildenafil from 
angina to erectile disfunction [6, 7]. It should be noted though, that drug repurposing is 
considerably faster when the approved dose is successfully repurposed, with additional 
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SARS-CoV-2 targets the angiotensin-converting enzyme 2 (ACE2) receptors that are present 
in high density on the outer surface of lung cells [1]. Lungs are the primary site of SARS-CoV-
2 replication and infection is usually initiated in the upper respiratory tract [8]. Symptoms 
that result in neurological, renal and hepatic dysfunction are also emerging due to the 
expression of ACE2 receptors in these organs [9-12]. Therefore, therapeutic concentrations 
of antiviral drugs are likely to be needed in the upper airways for treatment and prevention 
of infection, but sufficient concentrations are also likely to be required systemically for 
therapy to target the virus in other organs and tissues.  
 
The scale at which antiviral activity of existing medicines is being studied for potential 
repurposing against SARS-CoV-2 is unprecedented [13]. The authors recently reported an 
analysis which benchmarked reported in vitro activity of tested drugs against previously 
published pharmacokinetic exposures achievable with their licenced doses [14]. 
Importantly, this analysis demonstrated that the majority of drugs that have been studied 
for anti-SARS-CoV-2 activity are unlikely to achieve the necessary concentrations in the 
plasma after administration of their approved doses. While this analysis is highly influenced 
by the drugs selected for analysis to date and highly sensitive to the accuracy of the 
reported antiviral activity data, a number of candidate agents were identified with plasma 
exposures above the reported EC50/EC90 against SARS-CoV-2.  
 
One such drug, nitazoxanide, is a thiazolide antiparasitic medicine used for the treatment of 
cryptosporidiosis and giardiasis that cause diarrhoea [15, 16], and also has reported activity 
against anaerobic bacteria, protozoa and other viruses [17]. Several reports have confirmed 
the activity of nitazoxanide against SARS-CoV-2 in different cell types [18-21]. Importantly, 
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rapid deacetylation of nitazoxanide in blood means that the major systemic species of the 
drug in vivo is tizoxanide, which has been shown to exhibit similar in vitro inhibitory activity 
to nitazoxanide for rotaviruses [22], hepatitis B and C viruses [23, 24], other coronaviruses, 
noroviruses [25],influenza viruses and SARS-CoV-2 [20, 26-28]. As another respiratory virus, 
previous work on influenza may be useful to gain insight into the expected impact of 
nitazoxanide for SARS-CoV-2. Accordingly, the drug has been shown to selectively block the 
maturation of the influenza haemagglutinin glycoprotein at the post-translational stage [27, 
29] and a previous phase 2b/3 trial demonstrated a reduction in symptoms and viral 
shedding at a dose of 600 mg BID compared to placebo in patients with uncomplicated 
influenza [30]. Other potential benefits of nitazoxanide in COVID-19 may derive from its 
impact upon the innate immune response that potentiates the production of type 1 
interferons [31, 32] and bronchodilation of the airways through inhibition of TMEM16A ion 
channels [33]. As of 9th August 2020, a total of 19 trials are listed as either planned or 
recruiting on clinicaltrials.gov but all of these studies are focusing upon doses of ≤1000 mg 
BID nitazoxanide either alone or in combination with other agents [34]. However, there are 
currently no data within the public domain to support these doses for COVID-19. 
Nitazoxanide is relatively safe in humans and a review of the safety and minimum pricing 
was recently published [35]. Plasma concentrations of tizoxanide have demonstrated dose 
proportionality, but administration in the fed state increases the plasma exposure [36]. 
Thus, the drug is recommended for administration with food. 
 
The prerequisites for successful development of antiviral drugs for SARS-CoV-2 have yet to 
be elucidated and gaps in knowledge exist in terms of the exposure-response relationship. 
However, the lung has emerged as a clear site of primary infection, and pulmonary co-
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morbidities are a key driver of mortality in the sickest patients [37-39]. Therefore, in 
treatment of early disease at least it seems likely that successful antiviral regimens will 
require drugs to penetrate into the lung at sufficient concentrations to exert their activity. 
Using HIV as a paradigm for successful chemoprophylactic approaches, antiviral drugs also 
require penetration into key sites of transmission such as the anal and vaginal mucosa [40-
42]. Therefore, the authors hypothesise that drugs achieving concentrations in lung that 
exceed those needed for activity will underpin successful antiviral development.  
 
Physiologically based pharmacokinetic (PBPK) modelling is a computational tool that 
integrates human physiology and drug disposition kinetics using mathematical equations to 
inform the pharmacokinetic exposure using in vitro and drug physicochemical data [43]. 
Recently, several international groups have called for a more robust integration of clinical 
pharmacology principles into COVID-19 drug development [44, 45]. Accordingly, the aim of 
this study was to validate a PBPK model for tizoxanide following administration of 
nitazoxanide. Once validated, this model was first used to assess the plasma and lung 
exposures estimated to be achieved during a previous trial for uncomplicated influenza. 
Next, different nitazoxanide doses and schedules were simulated to identify those expected 
to provide tizoxanide plasma and lung trough concentrations (Ctrough) above the reported 




A previously published whole-body PBPK model consisting of compartments to represent 
select organs and tissues developed in Simbiology (MATLAB R2019a, MathWorks Inc., 
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Natick, MA, USA) was used in this study [46, 47]. Nitazoxanide physiochemical and drug-
specific parameters used in the PBPK model were obtained from literature sources as 
outlined in Table 1. The PBPK model was assumed to be blood-flow limited, with instant and 
uniform distribution in each tissue or organ and no reabsorption from the large intestine. 




One hundred virtual healthy adults (50% women, aged 20–60 years between 40–120 kg) 
were simulated. The required duration for successful SARS-CoV-2 antiviral activity has not 
yet been robustly elucidated but for clarity in presentation, the simulations were conducted 
over 5 days of dosing. It should be noted that similar exposures would be expected beyond 
this once the drug has reached steady-state pharmacokinetics. Patient demographics such 
as weight, BMI and height were obtained from CDC charts [48]. Organ weight/volumes and 
blood flow rates in humans were obtained from published literature sources [49, 50]. 
Transit from the stomach and small intestine was divided into seven compartments to 
capture effective absorption kinetics as previously described [51]. Tissue to plasma partition 
ratio of drug and drug disposition across various tissues and organs were described using 
published mathematical equations [52-54]. Effective permeability (Peff) in humans was 
scaled from apparent permeability (Papp) in HT29-19A cells (due to lack of available data, it 
was assumed the same in Caco-2 cells) using the following equations to compute the rate of 
absorption (Ka in h-1) from the small intestine. 
 
log10 𝑃𝑒𝑓𝑓  =  0.6836 × log10 𝑃𝑎𝑝𝑝 − 0.5579  [55] 
 
 





     [56] 
 
Model validation 
The PBPK model was validated against available clinical data in healthy individuals in the fed 
and fasted state for various single oral doses of nitazoxanide ranging from 500 mg to 4000 
mg [36, 57], and for multiple dosing at 500 mg and 1000 mg BID with food. Nitazoxanide 
absorption was considered using the available apparent permeability data (shown in Table 
1) and tizoxanide was assumed to form as soon as the drug reached systemic circulation as 
metabolic studies have shown it takes just 6 minutes for complete conversion into the 
active circulating metabolite, with no trace of nitazoxanide detected in plasma [58]. 
Therefore, tizoxanide parameters were used to define drug disposition. The elimination 
pathway of tizoxanide is not clear from the literature, therefore apparent clearance 
obtained from the literature was used as a first-order rate from the veinal compartment. 
Due to the unavailability of transporter pathways, a fixed absorption rate computed from 
apparent permeability was considered in the model. The model was assumed to be 
validated if: 1) the absolute average fold error (AAFE) between the observed and the 
simulated plasma concentrations–time curve of tizoxanide  was less than two; and 2) the 
simulated pharmacokinetic parameters–maximum concentration (Cmax), area under the 
plasma concentration–time curve (AUC) and Ctrough (trough concentration at the end of the 
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Model simulations 
The pharmacokinetics following administration of 600 mg BID as reported in a previous 
phase 2b/3 clinical trial of nitazoxanide in uncomplicated influenza [30] were first simulated 
and plotted relative to the average of previously reported influenza EC90s [59, 60] for strains 
(as shown in Supplementary Table 1) included in the previous trials. This was done to assess 
the exposure relative to in vitro activity for an indication where clinical benefit was already 
demonstrated. 
 
For potential SARS-CoV-2 applications, several oral dosing regimens were simulated for BID, 
TID or QID administration in the fasted state. Antiviral activity data from Wang et al. [18] 
were digitised using Web Plot Digitiser® software and used to calculate a nitazoxanide EC90 
for SARS-CoV-2 of 4.64 µM (1.43 mg/L). Optimal doses were identified such that the 
concentration at 12 h post-first dose (C12) for BID, 8 h post-first dose (C8) for TID, or 6 h post-
first dose (C6) for QID administration were over the recalculated EC90 for nitazoxanide. 
Plasma and lung tizoxanide exposures at these doses and schedules are reported in addition 
to plasma–time curves. The doses were optimised using tizoxanide parameters and 
pharmacokinetics; however, the doses were reported for nitazoxanide. 
 
Optimal pharmacokinetic sampling  
Clinical trials should incorporate pharmacokinetic sampling to confirm tizoxanide plasma 
exposures, and further validate the predictions from the PBPK model. Optimal sparse 
pharmacokinetic timepoint selection (assuming four blood samples per patient, and 40 
patients in the study) was made on the basis of the prior fed pharmacokinetic data of 
Stockis et al. [36, 57]. Tizoxanide plasma pharmacokinetic data in fed patients from Stockis 
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et al. was fitted with an empirical one-compartment disposition model, with first-order 
absorption and absorption transit compartment, and the parameters from this fitting were 
used (with nominal %CV interindividual variability in the pharmacokinetic parameters of 
30%) in the optimal design software PopDes (University of Manchester Version 4.0) to 
generate the suggested optimal sampling timepoints [61, 62]. 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 




The PBPK model validation against various fasted oral doses is shown in Figure S1 and the 
validation against single and multiple doses in the fed state is shown in Figure S2. The 
corresponding pharmacokinetic parameters (AUC, Cmax and Ctrough) are presented in Table 2 
and 3. The AAFE values for the validated doses ranged between 1.01–1.55 for fasted state 
and between 1.1–1.58 for fed state indicating a close match between observed and 
simulated data. The ratio between the simulated and the observed pharmacokinetic 
parameters – AUC, Cmax and Ctrough – was between 0.81–1.54 (Table 2) for fasted state and 
between 0.67–2.15 for fed state. The PBPK model simulated tizoxanide plasma 
concentrations were within acceptable ranges and therefore the PBPK model was assumed 
to be validated. 
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Model simulations 
Figure 1a and 1b show the simulated plasma and lung exposures relative to the average 
influenza EC90 after administration of 600 mg BID dose of nitazoxanide with food as 
reported in the previous phase 2b/3 trial in uncomplicated influenza [30]. These simulations 
indicate that all patients were predicted to have plasma and lung tizoxanide Ctrough (C12) 
concentrations below the average EC90  (8.4 mg/L, Table S1) [60], but that 71% and 14% 
were predicted to have plasma and lung Cmax concentrations, respectively, above the 
average EC90 for influenza, respectively. 
 
Figure 2a and 2b shows the prediction of trough concentrations in plasma and lung for the 
different simulated doses and schedules in healthy individuals for fasted and fed states, 
respectively. Doses and schedules estimated to provide plasma Ctrough concentrations over 
1.43 mg/L for at least 50% of the simulated population were identified. However, lower 
doses in each schedule (i.e. 800 mg QID, 1300 mg TID and 1800 mg BID in fasted state and 
500 mg QID, 700 mg TID and 1100 mg BID in fed state) were predicted to result in >40% of 
the simulated population having lung Ctrough below the SARS-CoV-2 EC90. Optimal doses for 
SARS-CoV-2 in the fasted state were predicted to be 1200 mg QID, 1600 mg TID and 2900 
mg BID, and in the fed state were 700 mg QID, 900 mg TID and 1400 mg BID. Figure 3 shows 
the plasma and lung concentrations for the optimal doses and schedules in fed state and 
Figure S3 shows the plasma concentration–time profile of optimal doses in fasted state. 
Tizoxanide concentrations in lung and plasma were predicted to reach steady state in <48 h, 
both in the fasted and fed state. 
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Optimal sparse sampling design  
Results from PopDes optimal design procedure indicate pharmacokinetic sampling 
timepoints at 0.25, 1, 3 and 12 h post dose for BID regimens, and 0.25, 1, 2 and 8 h post 
dose for TID regimens. 
Discussion 
Treatment of SARS-CoV-2 has become a major global healthcare challenge with no well-
defined therapeutic agents to either treat or prevent the spread of the infection. Short-term 
treatment options are urgently required but many ongoing trials are not based upon a 
rational selection of candidates in the context of safe achievable drug exposures. In the 
absence of a vaccine, there is also an urgent need for chemo preventative strategies to 
protect those at high risk such as healthcare staff, key workers and household contacts who 
are more vulnerable to infection. Nitazoxanide has emerged as a potential candidate for 
repurposing for COVID-19. The PBPK model presented herein was validated with an 
acceptable variation in AAFE and simulated/observed ratio (close to 1), which provides 
confidence in the presented predictions. The present study aimed to define the optimal 
doses and schedules for maintaining tizoxanide plasma and lung concentrations above the 
reported nitazoxanide EC90 for the duration of the dosing interval.  
 
Nitazoxanide was assessed in a double-blind, randomised, placebo-controlled, phase 2b/3 
trial (NCT01227421) of uncomplicated influenza in 74 primary care clinics in the USA 
between 27 December 2010 and 30 April 2011 [63]. The median duration of symptoms for 
patients receiving placebo was 117 h compared with 96 h in patients receiving 600 mg BID 
nitazoxanide with food. Importantly, virus titre in nasopharyngeal swabs in 39 patients 
receiving nitazoxanide 600 mg BID was also lower than in 41 patients receiving placebo. The 
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average of reported tizoxanide EC90s for influenza A and B [64] was calculated to be 8.4 
mg/L, which is higher than the one reported EC90 for nitazoxanide against SARS-CoV-2 [18]. 
The PBPK model was used to simulate plasma and lung exposures after administration of 
600 mg BID for 5 days, and while only plasma Cmax exceeded the average influenza EC90 in 
the majority of patients, the Ctrough values did not.  The modelling data suggest that the 
moderate effects of nitazoxanide seen in influenza could be a function of underdosing. 
Although influenza and SARS-CoV-2 both elicit pulmonary disease, it should be noted that 
the viruses are quite dissimilar. However, taken collectively when benchmarked against the 
in vitro activities of both viruses, these data are encouraging for the application of 
nitazoxanide in COVID-19. Moreover, these simulations indicate that higher doses may be 
optimal for maximal suppression of other pulmonary viruses. 
 
In some cases, food intake may be difficult in patients with COVID-19 so drugs that can be 
given without regard for food may be preferred. However, the presented predictions 
indicate that optimal plasma and lung exposures would require 1200 mg QID, 1600 mg TID 
or 2900 mg BID in the fasted state. Conversely, the PBPK models predict that doses of 700 
mg QID, 900 mg TID or 1400 mg BID with food provide tizoxanide concentrations in plasma 
and lung above the EC90 value for nitazoxanide for the entire dosing interval in at least 90% 
of the simulated population. Single doses up to 4000 mg have been administered to humans 
previously [36] but the drug is usually administered at 500 mg BID. The PBPK model 
simulations indicate a high BID dose of 1400 mg (fed) and caution may be needed for 
gastrointestinal intolerance at this dose. The simulations indicate that lower TID and QID 
dosing regimens may also warrant investigation, and 900 mg TID as well as 700 mg QID 
(both with food) regimens are also predicted to provide optimal exposures for efficacy. 
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Importantly, the overall daily dose was estimated to be comparable between the different 
optimal schedules and it is unclear whether splitting the dose will provide gastrointestinal 
benefits. For prevention application where individuals will need to adhere to regimens for 
longer durations, minimising the frequency of dosing is likely to provide adherence benefits. 
However, for short-term application in therapy, more frequent dosing may be more 
acceptable to minimise gastrointestinal intolerance. 
 
Nitazoxanide mechanism of action for SARS-CoV-2 is currently unknown. However, for 
influenza it has been reported to involve interference with N-glycosylation of 
haemagglutinin [27, 64, 65]. Since the SARS-CoV-2 spike protein is also heavily glycosylated 
[66] with similar cellular targets in the upper respiratory tract, a similar mechanism of action 
may be expected [8, 67]. An ongoing trial in Mexico is being conducted with 500 mg BID 
nitazoxanide with food [34] but these doses may not be completely optimal for virus 
suppression across the entire dosing interval.  
 
This analysis provides a rational dose optimisation for nitazoxanide for treatment and 
prevention of COVID-19. However, there are some important limitations that must be 
considered. PBPK models can be useful in dose prediction but the quality of predictions is 
only as good as the quality of the available data on which they are based. Furthermore, the 
mechanism of action for nitazoxanide for other viruses has also been postulated to involve 
an indirect mechanism through amplification of the host innate immune response [68], and 
this would not have been captured in the in vitro antiviral activity that informed the target 
concentrations for this dose prediction. The simulated population used in this modelling 
consisted of healthy individuals up to 60 years old, but many patients requiring therapy may 
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be older and have underlying comorbidities. To best knowledge, the impact of renal and 
hepatic impairment on pharmacokinetics of this drug have not been assessed and may 
impact the pharmacokinetics. Although the current PBPK model is validated against various 
single doses in the fasted state and few multiple doses when given with food, the model 
may predict with less accuracy for multiple doses due to the unavailability of clinical data for 
multiple dosing over 1000 mg. The unusual shape of the observed PK curve in Figure S1e 
(4000 mg, fasted state) and Figure S2d (3000 mg, fed state) may be an error in the sampling 
or due to the low number of individuals in the study and this cannot be captured using the 
PBPK model since the exact cause of this is unknown, but the AAFE values and the ratio 
between observed and simulated PK parameters is less than 2 which implies the model as 
validated. Also, the observed vs. simulated curve for preceding doses i.e. 3000 mg in fasted 
state (Figure S1d) and 2000 mg (Figure S2c) in fed state are on par and the informed optimal 
doses are below these doses (2900 mg, fasted and 1400 mg, fed) and therefore the 
predictions would not have any impact of deviations in this case. The presented models 
were validated using BID doses only, and confidence in the predictions for TID and QID 
doses may be lower. The clinical studies used for model validation were performed in a 
limited number of patients [36] and thus may underrepresent real inter-subject variability. 
Also, the disposition parameters (apparent clearance and rate of absorption) obtained for 
the PBPK model were from a fasted study of 500 mg BID, and the parameters were adjusted 
to validate the tizoxanide model in the fed state, which may limit confidence in the model at 
higher doses. Only one manuscript has described the in vitro activity of nitazoxanide against 
SARS-CoV-2 [18] and no data are available for tizoxanide. Reported in vitro data may vary 
across laboratories and due to this the predicted optimal doses may change. However, the 
reported comparable activity of nitazoxanide and tizoxanide against a variety of other 
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viruses (including other coronaviruses) does strengthen the rationale for investigating this 
drug for COVID-19 [22-24, 26, 27]. Recently, several international investigators with 
experience of protein binding and its application in successful therapy for other viruses 
initiated a discussion about protein binding to reach consensus on its correct interpretation 
for SARS-CoV-2 [69]. As an outcome of this consensus, care should be taken to neither over- 
nor under-represent its consequences. Unfortunately, assessment of the consequences of 
protein binding needs to involve empirical determination as part of the in vitro 
methodology, and none of the reported EC90 values for influenza or SARS-CoV-2 were 
protein binding-adjusted [18]. Tizoxanide is known to be highly protein bound (>99%) in 
plasma [70] butwhile this was used to estimate drug penetration into the lung, data were 
not available to correct the in vitro activity to make a robust assessment in relation to the 
free drug pharmacokinetics.  
 
The doses estimated to be necessary to maintain active tizoxanide concentrations in plasma 
and lung are considerably higher than the approved dose (500 mg BID) or other multiple 
dose studies that have been published to date. However, single doses of up to 4000 mg 
have been given safely to humans previously, and several of the authors recently reviewed 
the safety of nitazoxanide across the different doses at which it has been studied [35, 71]. 
Nitazoxanide appears to be a remarkably safe drug but the major concerns are likely to 
relate to gastrointestinal safety. Accordingly, the doses proposed here will require a clinical 
development pathway that robustly addresses the safety. As a first step, Unitaid have 
recently agreed funding and an independent scientific advisory board has approved 
inclusion of high dose nitazoxanide in the seamless phase I/IIa AGILE platform trial 
(www.agiletrial.net), subject to successful relevant ethical and regulatory approvals.  
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In summary, the developed PBPK model of nitazoxanide was successfully validated against 
clinical data and based on currently available data, optimal doses for COVID-19 were 
estimated to be 700 mg QID, 900 mg TID or 1400 mg BID with food. Should nitazoxanide be 
progressed into clinical evaluation for treatment and prevention of COVID-19, it will be 
important to further evaluate the pharmacokinetics in these population groups. In 
treatment trials particularly, intensive pharmacokinetic sampling may be challenging. 




What is the current knowledge on the topic?  
COVID-19, an acute respiratory infection caused by SARS-CoV-2, has been declared as a 
pandemic by the World Health Organization. Several repurposed drugs are being evaluated 
but currently there are no robustly validated treatment or preventative medicines or 
regimens. Nitazoxanide has shown in vitro activity against SARS-CoV-2, influenza and several 
other animal and human RNA viruses. 
What question did this study address?  
The manuscript describes the pharmacokinetics of tizoxanide, the active metabolite of 
nitazoxanide using a physiologically based pharmacokinetic (PBPK) model. The validated 
PBPK model was used to estimate the optimal doses required for SARS-CoV-2 treatment or 
prevention such that >90% of the simulated population would have tizoxanide 
concentrations in the plasma and lung above the reported 90% effective concentration 
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What does this study add to our knowledge? 
There are no reported studies that identify treatment regimens of nitazoxanide for SARS-
CoV-2 treatment or prevention. The current study provides support for alternative dosing 
regimens of nitazoxanide for SARS-CoV-2 treatment and prevention that exceeds antiviral 
EC90s in key tissues and organs for the duration of the dosing interval. 
How might this change clinical pharmacology or translational science? 
Efficacy of nitazoxanide has been demonstrated for uncomplicated influenza and the 
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Figure 1 Simulated plasma (a) and lung (b) concentration for nitazoxanide 600 mg BID for 5 
days with food relative to the average reported tizoxanide EC90 value for influenza strains 
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Figure 2. (a) Predicted tizoxanide Ctrough (BID – 12 h, TID – 8 h, QID – 6 h) for various dosing 
regimens of nitazoxanide in fasted state at the end of the first dose. Data are presented as 
mean and error bars represent standard deviation. The percentages adjacent to the bar 
chart indicate the percentages of simulated population over EC90 of nitazoxanide for SARS-
CoV-2. (b) Predicted tizoxanide Ctrough (BID – 12 h, TID – 8 h, QID – 6 h) for various dosing 
regimens of nitazoxanide in fed state at the end of the first dose. Data are presented as 
mean and error bars represent standard deviation. The percentages adjacent to the bar 
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Figure 3 Predicted plasma and lung concentrations for optimal doses during the fed state at 
different regimens reaching steady state – (a) 1400 mg BID, (b) 900 mg TID and (c) 700 mg 
QID. TIZ – tizoxanide, SD – standard deviation, solid red line indicates clinical Cmax of 1 g 
single dose at fed state [36], solid green line represents clinical Cmax of 500 mg single dose 
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Table 1 Nitazoxanide input parameters for the PBPK model. 
 
Parameter Nitazoxanide Tizoxanide 
Molecular weight 307.28 [15] 265.25 [56] 
*Protein binding >99% [15] >99% [53] 
Log P  1.63 [15] 3.2 [56] 
pKa (acidic) 8.3 [15] 6.7 [57] 
R 0.55 0.55 
Number of hydrogen bond donors 1 [15] 2 [56] 
Polar surface area 114.11 [15] 136 [56] 
Apparent permeability (cm/s) 1.11e-4 [58] - 
Apparent clearance (L/h) - 19.34 ± 4.97 [55] 
Volume of distribution (L) - 38.68 ± 14.02 [55] 
Half-life (h) - 1.38 ± 0.29 [55] 
R – blood to plasma ratio was predicted from Paixão et al. [36] – not available, apparent permeability was 
assessed in HT29-19A cells and this value was considered the same in caco-2 cells for tizoxanide  





This article is protected by copyright. All rights reserved. 







Observed Simulated Simulated/observed 
500 [40] *AUC0-12 h (µg.h/ml) 27.02 ± 6.24 24.32 ± 5.07 0.90 
*Cmax (µg/ml) 6.80 ± 1.32  6.47 ± 1.17 0.95 
†Ctrough (µg/ml) 0.106 0.119 ± 0.185 1.12 
1000 
[29] 













































^AUC0-24 h (µg.h/ml) 88.5 (53.5–146) 76.9 (60.1–
93.8) 
0.87 
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^†Ctrough (µg/ml) 2.48 2.44 (2.19–
2.67) 
0.98 
*Cmax and AUC0-12h are represented as arithmetic mean ± SD, ^Cmax and AUC0-24h are represented as 
geometric mean (mean – SD, mean + SD), †Ctrough is C12 and has been digitised from the 
pharmacokinetic curve as the geometric mean is not available, arithmetic mean is shown for 
observed and arithmetic mean (mean – SD, mean + SD) are shown for simulated data, ^Cmax, AUC0-24h 
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Table 3 Tizoxanide validation against observed data for various single and multiple oral 




































*AUC0-last (µg.h/ml) 85.9 (68.8–107) 91.3 (69–
113.5) 1.06 










144 (105–198) 90.9 (69–
112.8) 0.63 












109 (74.8–142) 0.99 
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90 (60.9–119) 0.94 












161 (125–196) 0.84 




^†Ctrough (µg/ml) 6.55 6.52 (5.04–
7.84) 0.99 
^Cmax and AUC are represented as geometric mean (mean – SD, mean + SD) and ^Cmax and AUC0-24h 
were normalised to a 1000 mg dose, ^Cmax and AUC0-24h were normalised to a 1000 mg dose, *AUC is 
represented as AUC0-∞ after the first dose for single and AUC0-12 on day 7, †Ctrough is C12 has been 
digitised from the pharmacokinetic curve as the geometric mean is not available, arithmetic mean is 
shown for observed and arithmetic mean (mean – SD, mean + SD) are shown for simulated data 
 
